Spermidine

Clinical Summary

Spermidine is a naturally occurring polyamine central to cellular autophagy, eIF5A hypusination, and mitochondrial quality control. Endogenous synthesis declines 30-50% with age. It is the "downstream executor" of fasting and rapamycin-induced autophagy — Hofer 2024 (PMIDs 39117797, 39212197) showed both caloric restriction and rapamycin REQUIRE endogenous spermidine for their autophagy effects.

The translational problem: oral supplementation does not reliably raise plasma polyamines. Two independent RCTs (Keohane 2024, Senekowitsch 2023) confirmed doses up to 40 mg/day produce minimal circulating spermidine rise in adults. This undercuts the pharmacokinetic premise of most commercial products.

Human RCT evidence is thin: the SmartAge trial (PMID 35616942, N=100, 12 months) MISSED its primary cognitive endpoint. The earlier Wirth 2018 pilot (PMID 30388439, N=28) was positive but not replicated. The strongest human signal is observational (Bruneck cohort: high dietary spermidine → 40% lower CVD risk, 5-7 mmHg BP reduction) — not yet confirmed in any completed RCT. POLYCAD (NCT06186102, N=180, elderly CAD) reads out 2027 and is the most important pending trial.

Food sources (natto, wheat germ, aged cheddar, mushrooms, soybeans) deliver higher doses at lower cost than capsules and carry the epidemiological evidence. Japanese folk practice (natto, miso) predates and outperforms Western capsule marketing. For capsules, wheat germ extract has the most trial exposure; synthetic trihydrochloride is purer but less studied.

Best candidates for supplementation: adults >60 seeking low-risk adjunct to diet + exercise + fasting; elderly with subclinical cognitive concern (if willing to accept uncertain benefit); dietary gaps (vegan, low-fermented-food intake). Not warranted as a longevity insurance pill based on current human data.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence. BH = Bradford Hill (/9). Safety flag = FAERS/trial signals for THIS specific indication. Star rating ≤ causal taxonomy ceiling.

Counter-signal to note: Chinese CATIS cohort (PMIDs 39817544, 39082415) — HIGH plasma polyamines associated with WORSE post-stroke cognition and 3-month outcomes. Likely reverse causation (tissue damage releases polyamines) but inverts the "more polyamines = more health" narrative. Re-evaluate if any dose-ceiling emerges.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication Stars: 5/5 multiple large RCTs + MA | 4/5 several human RCTs | 3/5 some human pilot | 2/5 animal or very limited human | 1/5 none or debunked

Prescribing

Dosing Table

EFSA Novel Food ceiling: 6 mg/day spermidine from wheat germ extract (Reg EU 2020/443). Safety studied up to 40 mg/day pharmaceutical-grade (PMID 39405978).

Formulation Table

Safety

Interactions Table

Contraindications

• Pregnancy and lactation — no supplementation safety data; dietary spermidine from normal varied diet is safe
• Pediatric population (<18) — endogenous synthesis is highest in youth; no pediatric safety/efficacy data
• Active cancer under treatment — autophagy can be tumor-suppressive OR tumor-promoting depending on cancer type and treatment phase; discuss with oncologist before use
• Wheat allergy or celiac disease — avoid wheat germ extract; use certified gluten-free formulations (rice germ or synthetic trihydrochloride)
• Concurrent autophagy inhibitor therapy — mechanistic antagonism; discuss with prescriber

Adverse Effects

Common (1-10%):

• Mild gastrointestinal effects — occasional bloating, mild gas, transient nausea. In SmartAge (N=100, 12 months) AE rates were balanced between spermidine and placebo groups. Management: take with food; temporarily reduce dose; usually resolves 1-2 weeks.

Uncommon (0.1-1%):

• Mild transient headache
• Subtle stimulatory sensation in sensitive individuals (dose-dependent)

Rare (<0.1%):

• No serious adverse events published in completed clinical trials (SmartAge, Wirth pilot, Keohane, Senekowitsch). Compliance >85% across 12-month trial.

Genotoxicity: Negative in bacterial reverse mutation and mammalian micronucleus assays (Chrysostomou 2024, PMID 38163454). 90-day oral toxicity study: no adverse effects at any tested dose.

Counter-signal (observational, Chinese cohorts): He 2025 CATIS cohort (PMID 39817544) and Yang 2024 (PMID 39082415) found elevated plasma polyamines associated with WORSE post-stroke cognition and adverse short-term outcomes. Direction likely reverse causation (tissue injury releases polyamines), but signal warrants attention if any proposed supplementation ceiling emerges. Guleroglu 2025 (PMID 39844083) separately found elevated endogenous polyamines in placental syndrome pathology.

FAERS Signal Table (from BioMCP, queried 2026-04-17)

Reading FAERS data: Total reports 2-7 depending on filter; spermidine is NOT the suspect drug in any retrieved report. All reactions attributable to co-suspect oncology drugs (abemaciclib, tazemetostat). FAERS under-captures dietary supplements (reporting funnel via DSHEA is minimal). Interpret as: no actionable FAERS signal exists for spermidine oral supplementation.

Monitoring Table

Special Populations (where dosing changes)

Renal Impairment

Hepatic Impairment

No dose adjustment needed across Child-Pugh A-C. Spermidine metabolized by multiple pathways (acetylation via SAT, oxidation via PAO); no hepatotoxicity observed in 90-day toxicology study (PMID 38163454) or 12-month human trial (PMID 35616942).

Pregnancy and Lactation

Avoid supplementation. No controlled studies. Dietary sources safe at normal intake. Rationale: autophagy modulation during critical developmental windows is unstudied; endogenous spermidine is essential for fetal development but supplementation effects unknown.

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

No other clinically significant sex-specific differences have been identified for spermidine.

Genetic Modifiers

Honest statement: No pharmacogenomic variants have been validated for spermidine supplementation response (searched 2024-2026). The polyamine biosynthesis enzymes (ODC1, SAT1, AZIN1, SMS) are the obvious candidates but no supplementation × genotype studies exist. Do not be persuaded by commercial "personalized longevity" genetic panels claiming to guide spermidine dosing — the evidence base is silent.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, affiliate-driven amplification, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

MIXED, leaning skeptical. Across r/Nootropics, r/Supplements, r/longevity, r/Biohackers, Longecity: spermidine generates few "I definitely felt this" reports compared to creatine or ashwagandha. Commonly filed as "longevity insurance — take and hope." Longecity analytical community is net-skeptical, citing the Keohane 2024 and Senekowitsch 2023 null bioavailability RCTs as reason to prefer food sources. Oxford Healthspan / Primeadine ecosystem generates the most enthusiastic reports, but these are heavily affiliate-driven.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• Affiliate ecosystem (NOT classic pyramid MLM): Oxford Healthspan / Primeadine operates a documented affiliate program (oxfordhealthspan.com/pages/register-affiliate-account). Commission on discount-code orders. Leslie Kenny appears on an unusually coordinated roster of podcasts (Nat Niddam, Jay Campbell, Dr. Stephanie Estima, Inside Out Health, Outliyr, etc.) — most hosts have affiliate codes. Treat all "Primeadine reversed my gray hair / autoimmune disease" testimonials from podcasters as paid content.
• Scientific advisory board conflicts: David Sinclair sits on SpermidineLIFE's scientific advisory board; Guido Kroemer and Frank Madeo (the most-cited autophagy researchers in the field) have commercial ties to Longevity Labs. This is a structural conflict that affects which mechanisms get amplified in reviews.
• Founder-origin-myth marketing: Leslie Kenny's unverified personal autoimmune-remission-at-39 story is the brand emotional anchor; repeated verbatim across dozens of podcasts.
• Industry concentration: Austrian wheat-germ extract cluster (Longevity Labs/spermidineLIFE, Kalin Health), emerging Portuguese synthetic (Chrysea Labs — sponsors 2 trials including their own N=6 bioavailability study), and Oxford Healthspan's Primeadine. Chrysea's N=6 study is a commercial dossier, not independent.
• Gray-hair claim: WIDESPREAD folk claim but driven almost entirely by Oxford Healthspan marketing ecosystem. ZERO human RCT support. One in-vitro melanogenesis paper. Debunked tier.
• Affiliate-monetized listicles: Every "top spermidine supplement" ranking (Outliyr, Innerbody, WellnessPulse, DecodeAge, BodyScienceReview, omre) is affiliate-driven. Rankings shift by commission rate, not evidence.
• Peter Attia notably absent: Attia does NOT include spermidine in his longevity stack and has not endorsed it — a meaningful signal from a skeptical longevity-space practitioner.
• No FDA warning letters, no recalls, no adulteration scandals specific to spermidine brands as of 2026-04-17.

Folk vs Clinical Reality Check

Folk evidence DIVERGES from clinical data in three major ways: (1) gray-hair reversal is a marketing-manufactured claim with zero RCT support but widespread anecdotal presence — likely placebo + affiliate amplification; (2) subjective cognitive benefit is inconsistently reported in the community but was NULL in the largest RCT (SmartAge); (3) community sleep benefits CONTRADICT a population study (PMC10828152) that found HIGHER spermidine associated with WORSE sleep microstructure in older adults. Folk evidence ALIGNS with clinical data on safety (both show excellent tolerability) and on food-first being the strongest-evidence approach (Japanese natto tradition + Bruneck epidemiology both outperform capsules). The Longecity community skeptical consensus (food beats capsules, bioavailability is questionable) matches the published pharmacokinetic RCTs more accurately than the Oxford Healthspan-driven hype cycle.

Deep Dive: Mechanisms & Research

Core Mechanism (post-2024 reframing)

Hofer 2024 (Nature Cell Biology, PMID 39117797) and Hofer 2024 (Autophagy, PMID 39212197) repositioned spermidine from "a supplement that induces autophagy" to "the downstream executor that CR, fasting, and rapamycin all require." Endogenous polyamine biosynthesis is necessary for fasting- and rapamycin-induced autophagy via eIF5A hypusination. This is mechanistically elegant but introduces a translational paradox: the benefits attributed to spermidine may be largely fasting/CR/rapamycin effects executed through endogenous spermidine, not effects achievable by oral supplementation — especially given that oral supplementation doesn't reliably raise plasma polyamines (Keohane 2024, Senekowitsch 2023).

Bioavailability: the unresolved problem

Two independent RCTs found oral spermidine supplementation does not meaningfully raise circulating polyamines:

• Senekowitsch 2023 (PMID 37111071): high-dose spermidine did NOT raise plasma/saliva spermidine in healthy adults
• Keohane 2024 (PMID 39405978): 40 mg/day trihydrochloride minimal effect on circulating polyamines in older men
• Chrysea Labs commercial PK study (NCT06017219): N=6, company-sponsored — interpret cautiously

Possible explanations: extensive first-pass metabolism (acetylation, oxidation to acrolein), tissue-level uptake unreflected in plasma, or genuine pharmacokinetic failure. Until resolved, claims that supplementation drives clinical effects through raised polyamine levels are unsupported by direct human PK data.

Mechanisms with documented clinical translation

• eIF5A hypusination — only known protein modification of its kind; required for translation of autophagy-related proteins. Animal and human fasting data confirm mechanism conservation.
• Cardiac autophagy — mouse data (PMID 27841876) and pending POLYCAD human trial.
• Endothelial function — Matsumoto 2019 (PMID 31137855) gut-polyamine induction via bifidobacteria/arginine improved endothelial function in N=44 Japanese adults (indirect, not oral spermidine).
• Doxorubicin cardiotoxicity prevention (Schirone 2026 PMID 41904730) — animal only.
• Stress-granule / condensation biology (Sun 2025 PMID 41271735) — spermine (not spermidine) modulates Tau/α-synuclein biomolecular condensation; mechanistically interesting for neurodegeneration, clinically premature.

Mechanisms still preclinical

• Mitophagy enhancement (PINK1/Parkin pathway) — strong cell/animal data, no human biomarker confirmation
• Epigenetic modulation (histone hypoacetylation via EP300 inhibition) — animal only
• Gut-polyamine modulation in IBD (Zhang 2026 PMID 41352542, Cai 2026 PMID 41776845, Li 2025 PMID 39924644) — all preclinical
• Hepatoprotection (Liu 2025 PMID 41090451 alcoholic liver, animal)
• Mendelian randomization for CAD (Wang 2025 PMID 41013818, Chinese) — suggestive genetic evidence; not interventional

Clinical Trials (ClinicalTrials.gov via BioMCP, queried 2026-04-17)

Key pending readout: POLYCAD (NCT06186102) — the most important upcoming spermidine trial, protocol published October 2025 (PMID 41168834). No Phase 3 longevity or cognitive trial is actively recruiting. The stalled Phase 3 Anti-Hypertension trial (NCT04405388) with no results posted is a yellow flag — either underpowered, negative, or financially abandoned.

Regulatory Status

• FDA: Not an approved drug. No GRAS determination for synthetic spermidine. Marketed as dietary supplement under DSHEA. No warning letters identified specific to spermidine.
• EMA: Not approved.
• EU Novel Food: Spermidine-rich wheat germ extract (Triticum aestivum, 0.8-2.4 mg/g spermidine) AUTHORIZED under Commission Implementing Regulation (EU) 2020/443. Maximum daily intake: 6 mg spermidine. Purified synthetic spermidine would require separate novel food authorization.
• EFSA health claims: All submitted health claims (immune, DNA/lipid protection, cardiovascular) REJECTED as insufficiently supported. This is a significant regulatory-skeptical data point.
• TGA (Australia): Listed as permissible ingredient in complementary medicines.
• Japan: FOSHU/functional food framework; no spermidine-specific health claim approved. Uemura group (Chiba) remains basic-science focused.
• DrugBank: DB03566. ChEMBL: CHEMBL19612. Research-reagent classification.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: "Natural polyamine found in all foods" — used to imply safety and efficacy; true for safety, weak for efficacy.
• Hasty generalization: Yeast/worm/fly lifespan extension → human longevity claims. Mechanism is conserved but clinical magnitude in humans is untested.
• Appeal to authority: Sinclair, Madeo, Kroemer endorsements — BUT these researchers have commercial ties to Longevity Labs / SpermidineLIFE. Authority is compromised.
• Cherry-picking: Wirth 2018 pilot (positive) cited more than SmartAge 2022 (primary negative) in marketing. Reverse of the evidence hierarchy.
• Argument from popularity: "80+ international research teams use SpermidineLIFE" — marketing without verification.
• Mechanism ≠ benefit: "Induces autophagy" ≠ "extends your life." Mechanism is necessary but not sufficient.
• Confusion of endogenous and supplemental: Hofer 2024 shows ENDOGENOUS spermidine is required for fasting/CR autophagy. This does NOT mean ORAL supplementation replicates those benefits.

Evidence Gaps

• Bioavailability unresolved after multiple RCTs: oral supplementation up to 40 mg/day does not reliably raise plasma polyamines
• No Phase 3 trial with posted results — stalled Anti-Hypertension Phase 3 (NCT04405388) is a yellow flag
• No completed RCT meta-analysis — the field lacks a quantitative synthesis
• No head-to-head against rapamycin, metformin, or NAD+ precursors (the competitors in geroprotection)
• No sex-stratified replication of the 2018 Kiechl signal
• No pharmacogenomic stratification — ODC1/SAT1/AZIN1/SMS variants never studied with supplementation
• No human RCTs for hair, skin, bone, sarcopenia, depression, or cancer endpoints
• POLYCAD readout pending 2027 — will be the first large RCT in elderly CAD
• Counter-signal (Chinese stroke cohorts) needs explanation — is elevated polyamine a damage marker or a causal risk factor?

Bias Flags (Mode 4: First Principles)

• Publication asymmetry: positive pilot (Wirth 2018, N=28) got disproportionate citation vs negative RCT (SmartAge 2022, N=100)
• Author commercial ties: Madeo, Kroemer, Sinclair are affiliated with Longevity Labs — the dominant wheat-germ extract manufacturer
• Epidemiology-first field: the Bruneck cohort drives most human claims; interventional evidence has not caught up
• No independent meta-analyst has synthesized the RCT evidence — every major review is from the Madeo/Kroemer orbit or is commercial-funded
• First-principles reframing after Hofer 2024: if endogenous spermidine is what matters for CR/fasting, then oral supplementation may be solving the wrong problem — you already have ample endogenous spermidine when you fast
• Cui bono on safety silence: with FAERS virtually empty and 12-month trials positive on safety, the supplement industry has a clean safety narrative. Cheap to market, cheap to defend. The fact that no one is running Phase 3 for cognition or mortality endpoints suggests ROI is insufficient to justify definitive trials.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing patterns: Austrian wheat germ extract cluster (Longevity Labs/SpermidineLIFE) uses "used in clinical trials" framing that conflates safety trials with efficacy trials; Oxford Healthspan (Primeadine) uses gray-hair-reversal narrative with no RCT support; Chrysea Labs runs their own bioavailability PK study as a commercial dossier.
• Influencer economics: Leslie Kenny (Oxford Healthspan CEO) runs an unusually coordinated podcast pipeline — most hosts carry Primeadine affiliate codes. David Sinclair endorsements are compromised by his SAB role at Longevity Labs. Siim Land enthusiastic; Rhonda Patrick measured; Peter Attia notably silent (meaningful negative signal).
• Counter-narrative: There is no significant pharma "FUD" against spermidine — it's not patentable, not competing with a pharma product. The suppression-narrative is weak because there is no suppressor.
• Cui bono summary:
  • Who profits if you take it: Longevity Labs (SpermidineLIFE), Oxford Healthspan (Primeadine), Kalin Health, Chrysea Labs, Double Wood, Nutraland, affiliate podcasters, listicle sites.
  • Who profits if you don't: No significant anti-spermidine commercial actor exists. This is a key asymmetry — all the manipulation pressure is pro-supplementation.
  • Food-first outcome: Natto producers, traditional food cultures; dietary spermidine requires no supplement industry and generates no affiliate revenue — which is likely why this message is under-amplified.
• Red team highlight: the single most concerning angle is the BIOAVAILABILITY FAILURE combined with AUTHOR COMMERCIAL TIES. If oral supplementation doesn't raise plasma polyamines and the field's most-cited researchers have commercial stakes in oral supplementation products, the publication record of "spermidine supplementation benefits" is structurally vulnerable. Hofer 2024 implicitly fixes this by pivoting to "endogenous spermidine matters" — but this reframing, if taken literally, argues for fasting and exercise over supplements.
• 10-angle red team summary: Logical consistency — claims overstate human evidence. Evidence quality — only 2 RCTs, one positive one null. Cui bono — all pro, no anti. Time horizon — "longevity" benefit untestable in product lifecycle. Steelman — CV epidemiology is genuinely strong and POLYCAD is a credible pending test. Reversibility — stopping is harmless. Second-order — natto + fasting obviates the need. Historical precedent — resveratrol/NR pattern (strong preclinical, disappointing human RCTs) is the reference class. Emotional loading — "gray hair reversal" exploits aging anxiety. Stranger test — if a stranger told you "take this pill to live longer, by the way it doesn't reach your blood," would you?

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 4/10 — compound-intrinsic score based on evidence quality + strongest indication + cross-domain breadth. Autophagy mechanism (4/5, DC) is elegant and real, but supplementation bioavailability and clinical endpoint translation are weak. CV epidemiology (3/5, OA) is the strongest human signal but not yet RCT-confirmed. Cognitive benefit failed its largest RCT. The mechanism is better approached by fasting, exercise, and food-first sources than by capsules. Evaluated independently of any stack.
• Opportunity cost: Low financial cost ($20-40/month wheat germ extract), low complexity (once daily), minimal safety risk, minimal pill burden. Main opportunity cost is attention: time spent researching/optimizing spermidine is time not spent on higher-utility interventions (exercise, sleep, protein, fasting).
• Hell Yes or No (Sivers test): No. The evidence does not clear a "hell yes" bar for general use.
• Regret minimization: In 5 years, would you regret NOT having tried spermidine? Probably not — the downside of non-use is tiny (food sources cover it), and better evidence is pending (POLYCAD 2027).
• Verdict: CONDITIONAL

Conditions that would warrant use:

• Adult >60 with subjective cognitive concern who has already optimized diet, sleep, exercise, fasting — AND accepts that the largest RCT missed its primary endpoint; a 3-6 month trial at 0.9-1.2 mg/day wheat germ extract is reasonable low-cost, low-risk
• Cardiovascular risk patient seeking low-intensity adjunct to established lifestyle and medical therapy, willing to wait for POLYCAD readout
• Individual with demonstrably low dietary polyamine intake (no natto, no aged cheese, no wheat germ, no mushrooms, no legumes) — preferred intervention is dietary repair, not supplementation
• Rapamycin user wanting to potentiate autophagy mechanism (Hofer 2024 rationale) — discuss with prescriber

Conditions that would warrant SKIP:

• Expecting gray-hair reversal, cognitive sharpening, or mood benefit — evidence does not support these
• Active cancer under treatment — discuss with oncologist
• Pregnancy, lactation, or pediatric — do not supplement
• Already getting ample dietary spermidine (Japanese-style diet, wheat germ in regular rotation) — food covers it

Bottom Line

Spermidine is a real molecule with robust preclinical biology that has not translated into convincing human RCT evidence despite a decade of research. The two RCTs that have matured (SmartAge, Keohane 2024) produced null results on the things that matter most — primary cognitive outcomes and plasma bioavailability. The epidemiological signal from Bruneck is genuine but unconfirmed by intervention. The most important pending trial is POLYCAD (2027). Until then, the rational posture is: food-first (natto, wheat germ, aged cheese), skip the gray-hair marketing, be skeptical of "used in trials" framing (trials showed safety, not efficacy), and spend optimization effort on fasting, exercise, and sleep — which Hofer 2024 shows REQUIRE endogenous spermidine for their autophagy benefits anyway.

Practical Notes

Brands & Product Selection

Quality markers to demand: USP Verified / NSF Certified / ConsumerLab approved; batch-specific Certificate of Analysis; spermidine content explicitly stated (e.g., "1 mg per capsule"); heavy metals <5 ppm total; gluten-free certification if celiac.

Red flags to avoid: proprietary blends with undisclosed spermidine content; "clinical strength" claims with no trial reference; affiliate-heavy listicle endorsements; gray-hair reversal or "reverse biological age" claims on product copy; Oxford Healthspan Primeadine and Longevity Labs SpermidineLIFE should be evaluated against their commercial bias, not endorsed by default.

Storage & Handling

• Temperature: room temperature (15-25°C / 59-77°F); refrigeration optional
• Light: keep in original opaque container; spermidine is relatively photostable
• Humidity: KEEP DRY — raw synthetic spermidine is hygroscopic and can deliquesce; wheat germ extract capsules less affected
• Shelf life: 2 years unopened; 12-18 months after opening
• Raw synthetic spermidine SDS: eye irritant, skin burns on prolonged contact — a Longecity-flagged concern for users handling powder directly

Palatability & Compliance

• Wheat germ extract capsules: mild nutty flavor if opened; unobtrusive
• Spermidine trihydrochloride: slightly salty, neutral; powder can be mixed into food
• Food-first approach beats supplementation for compliance if you already eat natto, wheat germ, or aged cheese
• Daily morning dosing aligns with SmartAge protocol and gives best adherence

Exercise & Circadian Timing

• Morning with breakfast — aligns with autophagy gene expression peaks; matches all RCTs
• Fasting window compatibility: can be taken during extended fasts; Hofer 2024 shows fasting requires endogenous spermidine, so exogenous during fasting is mechanistically coherent (though not pharmacokinetically demonstrated)
• Post-workout: no evidence of ergogenic or recovery benefit; unnecessary timing anchor
• Evening dosing: some users report mild stimulation; avoid pre-sleep initially

Reference Ranges (Expected Biomarker Changes)

Cost

Cost-effectiveness: raw wheat germ (Longecity DIY) is cheapest and provides dose equivalent to branded capsules; Japanese diet is most evidence-aligned; synthetic trihydrochloride carries the weakest cost:benefit given negative bioavailability data.

What We Don't Know

• Whether oral spermidine supplementation at any dose meaningfully raises tissue polyamine levels (plasma says no; tissue level data absent)
• Whether the Bruneck CVD signal will confirm in a completed RCT (POLYCAD readout 2027)
• Whether positive pilot cognitive findings (Wirth 2018) will ever replicate, and if so at what dose and duration
• Whether the Chinese stroke cohort elevated-polyamine signal represents reverse causation, a dose-ceiling, or a distinct pathological subset
• Whether ODC1/SAT1/AZIN1/SMS genetic variants modify supplementation response
• Whether any meaningful sex-specific difference beyond the 2018 Kiechl signal exists and replicates
• Whether spermidine + rapamycin, spermidine + metformin, or spermidine + NAD+ combos add value in humans (no head-to-head or combination RCT exists)
• Whether hair, skin, bone, sarcopenia, mood, or autoimmune endpoints have any human validity beyond marketing claims
• Whether food-matrix spermidine (natto, wheat germ) beats purified capsules for clinical outcomes — strongly suggested by epidemiology, never directly tested in RCT
• Whether Hofer 2024's "endogenous spermidine executes CR/fasting/rapamycin benefits" framework means oral supplementation is redundant when fasting/exercise are practiced
• Long-term effects beyond 12 months (longest human trial duration to date)
• Pediatric safety (zero data)

References

Landmark RCTs

1. Schwarz C et al. 2022. Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline. JAMA Netw Open 5(5):e2213875. PMID: 35616942. SmartAge trial, N=100, 12 months, 0.9 mg/day wheat germ. Primary cognitive endpoint NEGATIVE; exploratory verbal memory and inflammation signals.
2. Wirth M et al. 2018. Spermidine on memory performance in older adults at risk for dementia. Cortex 109:181-188. PMID: 30388439. Pilot N=28, 3 months, d=0.77 memory improvement. NOT replicated in SmartAge.
3. Keohane P et al. 2024. Supplementation of spermidine at 40 mg/day has minimal effects on circulating polyamines. Nutr Res 132:1-14. PMID: 39405978. Double-blind RCT in older men. NEGATIVE bioavailability.
4. Senekowitsch S et al. 2023. High-dose spermidine supplementation does not increase plasma or saliva spermidine. Nutrients (PMID: 37111071). Independent replication of bioavailability failure.
5. Iorio-Siciliano V et al. 2024. Spermidine + CaCl2 adjunct for peri-implant mucositis. Double-blind RCT. PMID: 39304548. Single positive local trial.
6. Schwarz C et al. 2018. Safety and tolerability of spermidine supplementation. Aging 10(1):19-33. PMID: 29315079. Phase IIa safety, N=30, excellent tolerability, >85% compliance.
7. Pekar T et al. 2021. 3-month open-label spermidine in dementia. Wien Klin Wochenschr. PMID: 33211152. MMSE stabilization, N=85.
8. Bruno et al. 2025. Rice germ extract pilot on healthy aging biomarkers. Altern Ther Health Med (low-tier journal). PMID: 40862848. Open-label, proof-of-concept.

POLYCAD & Protocol Publications

9. Thorup LB et al. 2025. POLYCAD protocol: polyamine treatment in elderly CAD. Trials. PMID: 41168834. NCT06186102, N=180, readout 2027.
10. Schwarz C et al. 2019. SmartAge protocol. Alzheimers Res Ther. PMID: 31039826.

Landmark Mechanism / Epidemiology

11. Eisenberg T et al. 2016. Cardioprotection and lifespan extension by spermidine. Nat Med 22(12):1428-1438. PMID: 27841876. Bruneck epidemiology (N=829, 20-yr) + mouse cardioprotection.
12. Eisenberg T et al. 2009. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 11(11):1305-1314. PMID: 19801973. Landmark yeast/worm/fly lifespan extension paper.
13. Hofer SJ et al. 2024. Spermidine is essential for fasting-mediated autophagy and longevity. Nat Cell Biol 26(9):1571-1584. PMID: 39117797. Reframed spermidine as downstream executor of CR.
14. Hofer SJ et al. 2024. Endogenous spermidine required for rapamycin-induced autophagy. Autophagy. PMID: 39212197.
15. Schroeder S et al. 2021. Dietary spermidine improves cognitive function (mouse). Cell Rep 35(2):108985. PMID: 33852843.
16. Tahara Y et al. 2025. Opposite effects of spermidine vs GC7 dictated by distinct molecular targets. Biochem J. PMID: 41408852.
17. Uemura et al. 2026. Polyamine metabolism as aging regulator. Amino Acids review. PMID: 41617890.
18. Sun Y et al. 2025. Spermine modulates Tau/α-synuclein biomolecular condensation. Nat Commun. PMID: 41271735. Mechanistically interesting for neurodegeneration; preclinical.
19. Schirone L et al. 2026. Spermidine prevents doxorubicin cardiomyopathy. PMID: 41904730. Preclinical.

Reviews

20. Hofer SJ, Simon AK, Bergmann M, Eisenberg T, Kroemer G, Madeo F. 2022. Mechanisms of spermidine-induced autophagy and geroprotection. Nat Aging 2(12):1112-1129. PMID: 37118547. NOTE: author commercial ties to Longevity Labs.
21. Guarente L, Sinclair DA, Kroemer G. 2024. Human trials exploring anti-aging medicines. Cell Metab 36(2):354-376. PMID: 38181790. NOTE: all three authors have commercial conflicts in the longevity space.
22. Borsky et al. 2025. Urolithin A vs spermidine in mitophagy/autophagy. Nutr Res Rev. PMID: 41404767.
23. Abdellatif et al. 2025. CV aging review. PMID: 39172536.
24. Liberale L et al. 2025. CV aging. Nat Rev Cardiol. PMID: 39972009.
25. Veronesi F et al. 2024. Circulating biomarkers in sarcopenia SR. PMID: 39521148.

Safety / Toxicology

26. Chrysostomou PP et al. 2024. Toxicological assessment of spermidine trihydrochloride from engineered S. cerevisiae. Food Chem Toxicol 184:114428. PMID: 38163454. GLP-compliant genotoxicity + 90-day oral tox; no adverse effects.

Counter-Signal Evidence (Chinese Stroke Cohorts + Placental Syndrome)

27. He et al. 2025. CATIS Chinese stroke cohort: elevated plasma polyamines → worse post-stroke cognition. J Am Heart Assoc. PMID: 39817544.
28. Yang et al. 2024. Stroke cohort: elevated polyamines adverse short-term outcomes. PMID: 39082415.
29. Guleroglu FY et al. 2025. Placental syndrome polyamine study. PMID: 39844083.

East Asian Evidence

30. Ikagawa et al. 2026. Japanese cohort: gut-derived polyamines and mean BP. Hypertens Res. PMID: 41413233.
31. Wang et al. 2025. Mendelian randomization: spermidine × CAD risk (bidirectional LC-MS/MS). Hereditas. PMID: 41013818.
32. Matsumoto M et al. 2019. Gut polyamine induction improved endothelial function. Nutrients. PMID: 31137855. N=44 Japanese adults.
33. Watanabe et al. 2025. Lubiprostone Phase 2 in CKD; polyamine biomarker. Sci Adv. PMID: 40880481.

IBD / Gut / Hepatic Preclinical

34. Zhang et al. 2026. Spermidine inhibits ferroptosis in UC. PMID: 41352542.
35. Cai et al. 2026. Agarotriose + Akkermansia → spermidine → colitis relief. PMID: 41776845.
36. Li et al. 2025. De novo microbial polyamine biosynthesis in IBD. PMID: 39924644.
37. Liu et al. 2025. Mung bean → spermidine → alcoholic liver injury. Food Funct. PMID: 41090451.
38. Jang et al. 2026. HCC sorafenib + polyamine. PMID: 41608628.

Fasting-Mimetic Combo Trials (spermidine not isolated)

39. Rhodes M et al. 2024. Mimio fasting mimetic pilot (spermidine + NAM + PEA + OEA). Nutr Res. PMID: 39549554.
40. Grant et al. 2026. Mimio RCT: hunger control, oxidative stress, cardiometabolic. Sci Rep. PMID: 41720867.

Bone / Cold Stress (Tangential)

41. Chevalier C et al. 2020. Warmth prevents bone loss through gut microbiota and polyamine biosynthesis. PMID: 32916104. Mouse.

Diabetic Nephropathy Preclinical

42. Source: 2024 preclinical spermidine-podocyte study. PMID: 39511379.

Depression Preprint (not peer-reviewed)

43. Mackert et al. 2024. Spermidine + depression via stress response. bioRxiv. PMID: 39677641. NOT peer-reviewed.

Additional Resources

• NIH Office of Dietary Supplements: No dedicated spermidine fact sheet (polyamines not classified as essential nutrients)
• Examine.com: https://examine.com/supplements/spermidine/
• ClinicalTrials.gov: 18 registered spermidine trials as of 2026-04-17
• EU Novel Food Regulation 2020/443: authorizes spermidine-rich wheat germ extract at max 6 mg/day spermidine
• EFSA opinion on health claims: REJECTED (immune, DNA/lipid protection, cardiovascular)
• DrugBank: DB03566 | ChEMBL: CHEMBL19612